Jazz Pharmaceuticals PLC Company Profile (NASDAQ:JAZZ)

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals PLC logoJazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder. Its marketed products and late-stage product candidate are Xyrem (sodium oxybate) oral solution, Luvox CR (fluvoxamine maleate) Extended-Release Capsules and JZP-6 (sodium oxybate). Its other product candidates in clinical development are oral tablet forms of sodium oxybate; JZP-8 (intranasal clonazepam); JZP-4 (elpetrigine), and JZP-7 (ropinirole gel).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: JAZZ
  • CUSIP: G5087110
Key Metrics:
  • Previous Close: $137.19
  • 50 Day Moving Average: $122.69
  • 200 Day Moving Average: $120.22
  • 52-Week Range: $95.80 - $160.00
  • Trailing P/E Ratio: 23.99
  • Foreward P/E Ratio: 12.02
  • P/E Growth: 0.79
  • Market Cap: $8.22B
  • Outstanding Shares: 59,892,000
  • Beta: 1.22
  • Net Margins: 24.81%
  • Return on Equity: 30.50%
  • Return on Assets: 13.21%
  • Debt-to-Equity Ratio: 1.25%
  • Current Ratio: 3.20%
  • Quick Ratio: 3.06%
Additional Links:
Companies Related to Jazz Pharmaceuticals PLC:

Analyst Ratings

Consensus Ratings for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) (?)
Ratings Breakdown: 1 Hold Rating, 14 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $181.85 (33.78% upside)

Analysts' Ratings History for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
DateFirmActionRatingPrice TargetDetails
2/21/2017MizuhoBoost Price TargetBuy -> Buy$127.00 -> $152.00View Rating Details
2/16/2017GuggenheimReiterated RatingBuyView Rating Details
2/15/2017BMO Capital MarketsReiterated RatingTop Pick$192.00View Rating Details
2/8/2017Deutsche Bank AGSet Price TargetBuy$148.00View Rating Details
1/24/2017Cantor FitzgeraldReiterated RatingOverweight$187.00View Rating Details
1/18/2017Leerink SwannReiterated RatingBuyView Rating Details
1/19/2017SunTrust Banks, Inc.Reiterated RatingBuy$210.00View Rating Details
1/18/2017Goldman Sachs Group, Inc. (The)Reiterated RatingBuy$170.00View Rating Details
1/18/2017Barclays PLCReiterated RatingOverweight$200.00View Rating Details
8/25/2016Janney Montgomery ScottInitiated CoverageNeutralView Rating Details
8/10/2016Piper Jaffray CompaniesLower Price TargetOverweight$188.00 -> $178.00View Rating Details
6/18/2016Wells Fargo & CompanyReiterated RatingBuyView Rating Details
4/5/2016Canaccord GenuityReiterated RatingBuy$170.00View Rating Details
4/1/2016Northland SecuritiesReiterated RatingOutperform$175.00View Rating Details
3/19/2016J P Morgan Chase & CoReiterated RatingBuyView Rating Details
2/24/2016Stifel NicolausLower Price TargetBuy$225.00 -> $200.00View Rating Details
11/25/2015Sanford C. BernsteinInitiated CoverageMarket Perform$160.00View Rating Details
11/10/2015Cowen and CompanyReiterated RatingBuyView Rating Details
3/27/2015Citigroup Inc.Initiated CoverageBuy$195.00View Rating Details
(Data available from 2/21/2015 forward)


Earnings History for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/28/2017ListenView Earnings Details
11/8/2016Q316$2.61$2.57$389.34 million$374.00 millionViewListenView Earnings Details
8/9/2016Q216$2.80$2.63$376.40 million$381.00 millionViewN/AView Earnings Details
5/10/2016Q1$2.31$2.26$338.86 million$336.00 millionViewListenView Earnings Details
2/23/2016Q415$2.60$2.60$349.98 million$340.90 millionViewListenView Earnings Details
11/9/2015Q315$2.56$2.52$348.15 million$340.90 millionViewListenView Earnings Details
8/5/2015Q215$2.41$2.41$335.58 million$333.70 millionViewListenView Earnings Details
5/7/2015Q115$2.15$1.99$309.50 million$309.30 millionViewListenView Earnings Details
2/24/2015Q414$2.30$2.44$319.74 million$328.10 millionViewListenView Earnings Details
11/4/2014Q314$2.23$2.33$302.90 million$306.58 millionViewListenView Earnings Details
8/5/2014Q214$1.92$2.05$273.39 million$291.23 millionViewListenView Earnings Details
5/8/2014Q114$1.79$1.61$254.86 million$247.00 millionViewListenView Earnings Details
2/25/2014Q413$1.78$1.72$238.12 million$235.80 millionViewListenView Earnings Details
11/5/2013Q313$1.67$1.78$227.38 million$232.20 millionViewListenView Earnings Details
8/6/2013Q2 2013$1.52$1.43$208.71 million$208.30 millionViewListenView Earnings Details
5/7/2013Q1 2013$1.35$1.37$189.92 million$196.20 millionViewListenView Earnings Details
2/26/2013Q4 2012$1.41$1.53$183.80 million$183.70 millionViewListenView Earnings Details
11/8/2012Q312$1.31$1.29$178.57 million$175.50 millionViewN/AView Earnings Details
8/7/2012$1.05$1.09ViewN/AView Earnings Details
5/8/2012$0.90$0.91ViewN/AView Earnings Details
11/1/2011$0.89$0.94ViewN/AView Earnings Details
7/28/2011$0.67$0.82ViewN/AView Earnings Details
5/3/2011$0.57$0.59ViewN/AView Earnings Details
3/7/2011$0.60$0.63ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
Current Year EPS Consensus Estimate: $9.96 EPS
Next Year EPS Consensus Estimate: $11.31 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162$1.39$1.48$1.44
Q2 20161$1.92$1.92$1.92
Q3 20162$1.58$2.02$1.80
Q4 20162$2.26$2.38$2.32
Q2 20171$2.84$2.84$2.84
Q3 20171$2.47$2.47$2.47
Q4 20171$2.78$2.78$2.78
(Data provided by Zacks Investment Research)


Dividend History for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
Insider Ownership Percentage: 3.90%
Institutional Ownership Percentage: 88.56%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/15/2017Michael Patrick MillerSVPSell200$134.55$26,910.00View SEC Filing  
1/18/2017Russell J. CoxCOOSell4,000$128.75$515,000.00View SEC Filing  
1/17/2017Michael Patrick MillerSVPSell200$115.93$23,186.00View SEC Filing  
12/15/2016Michael Patrick MillerSVPSell200$103.09$20,618.00View SEC Filing  
12/2/2016Patrick G EnrightDirectorSell677$101.80$68,918.60View SEC Filing  
11/15/2016Michael Patrick MillerSVPSell200$112.19$22,438.00View SEC Filing  
11/14/2016Kenneth W O'keefeDirectorBuy2,000$113.84$227,680.00View SEC Filing  
10/17/2016Michael Patrick MillerSVPSell200$118.16$23,632.00View SEC Filing  
9/19/2016Michael Patrick MillerSVPSell200$126.17$25,234.00View SEC Filing  
8/25/2016Seamus MulliganDirectorSell27,968$128.32$3,588,853.76View SEC Filing  
8/16/2016Paul TreacySVPSell1,292$137.47$177,611.24View SEC Filing  
8/15/2016Michael Patrick MillerSVPSell100$136.45$13,645.00View SEC Filing  
8/15/2016Rick E WinninghamDirectorSell633$136.45$86,372.85View SEC Filing  
8/12/2016Karen L SmithInsiderBuy608$137.10$83,356.80View SEC Filing  
8/9/2016Bruce C. CozaddCEOSell1,000$150.00$150,000.00View SEC Filing  
8/9/2016Russell J. CoxCOOSell4,000$148.66$594,640.00View SEC Filing  
7/15/2016Michael Patrick MillerSVPSell100$142.43$14,243.00View SEC Filing  
7/13/2016Karen L SmithCMOBuy580$143.63$83,305.40View SEC Filing  
6/15/2016Michael Patrick MillerSVPSell100$149.64$14,964.00View SEC Filing  
6/13/2016Karen L SmithCMOBuy557$149.61$83,332.77View SEC Filing  
5/16/2016Heather Ann McsharryDirectorSell697$145.20$101,204.40View SEC Filing  
5/16/2016Michael Patrick MillerSVPSell100$145.20$14,520.00View SEC Filing  
4/25/2016Karen J WilsonSVPSell604$160.00$96,640.00View SEC Filing  
4/15/2016Michael Patrick MillerSVPSell100$145.79$14,579.00View SEC Filing  
4/13/2016Karen J WilsonSVPSell5,007$150.00$751,050.00View SEC Filing  
4/12/2016Russell J CoxCOOSell4,000$136.98$547,920.00View SEC Filing  
4/7/2016Karen J WilsonSVPSell2,161$140.90$304,484.90View SEC Filing  
3/15/2016Michael Patrick MillerSVPSell100$129.17$12,917.00View SEC Filing  
3/8/2016Bruce C CozaddCEOSell2,500$126.04$315,100.00View SEC Filing  
2/29/2016Paul TreacySVPSell354$123.48$43,711.92View SEC Filing  
2/23/2016Seamus MulliganDirectorSell27,968$122.71$3,431,953.28View SEC Filing  
2/16/2016Michael Patrick MillerSVPSell100$115.63$11,563.00View SEC Filing  
2/10/2016Patrick G EnrightDirectorSell10,000$117.92$1,179,200.00View SEC Filing  
2/9/2016Bruce C CozaddCEOSell2,500$111.37$278,425.00View SEC Filing  
1/15/2016Michael Patrick MillerSVPSell100$122.66$12,266.00View SEC Filing  
1/12/2016Bruce C CozaddCEOSell2,500$123.81$309,525.00View SEC Filing  
1/5/2016Patrick G EnrightDirectorSell10,000$138.09$1,380,900.00View SEC Filing  
12/15/2015Michael Patrick MillerSVPSell100$136.99$13,699.00View SEC Filing  
12/8/2015Bruce C CozaddCEOSell2,500$139.72$349,300.00View SEC Filing  
12/2/2015Patrick G EnrightDirectorSell10,424$146.67$1,528,888.08View SEC Filing  
11/23/2015Seamus MulliganDirectorSell27,968$145.86$4,079,412.48View SEC Filing  
11/10/2015Bruce C CozaddCEOSell2,500$128.53$321,325.00View SEC Filing  
11/10/2015Patrick G EnrightDirectorSell10,000$135.29$1,352,900.00View SEC Filing  
10/21/2015Suzanne Sawochka HooperEVPSell2,000$125.00$250,000.00View SEC Filing  
10/13/2015Bruce C CozaddCEOSell2,500$131.50$328,750.00View SEC Filing  
10/5/2015Patrick G EnrightDirectorSell10,000$133.79$1,337,900.00View SEC Filing  
9/25/2015Michael Patrick MillerSVPSell100$145.23$14,523.00View SEC Filing  
9/8/2015Bruce C. CozaddCEOSell2,500$163.07$407,675.00View SEC Filing  
9/1/2015Patrick G EnrightDirectorSell10,000$165.99$1,659,900.00View SEC Filing  
7/14/2015Bruce C CozaddCEOSell5,000$177.79$888,950.00View SEC Filing  
7/14/2015Suzanne Sawochka HooperEVPSell4,000$177.79$711,160.00View SEC Filing  
7/6/2015Patrick G EnrightDirectorSell10,000$177.11$1,771,100.00View SEC Filing  
6/9/2015Bruce C CozaddCEOSell5,000$173.16$865,800.00View SEC Filing  
6/9/2015Suzanne Sawochka HooperEVPSell4,000$173.16$692,640.00View SEC Filing  
6/2/2015Karen J WilsonSVPSell5,751$179.59$1,032,822.09View SEC Filing  
6/1/2015Karen J WilsonSVPSell5,494$179.57$986,557.58View SEC Filing  
4/14/2015Bruce C CozaddCEOSell5,000$181.45$907,250.00View SEC Filing  
4/14/2015Suzanne Sawochka HooperEVPSell4,000$181.45$725,800.00View SEC Filing  
3/25/2015Seamus MulliganDirectorSell50,000$174.59$8,729,500.00View SEC Filing  
1/5/2015Patrick G EnrightDirectorSell10,000$160.25$1,602,500.00View SEC Filing  
12/26/2014Seamus MulliganDirectorSell50,000$163.40$8,170,000.00View SEC Filing  
12/12/2014Patrick G EnrightDirectorSell2,343$170.98$400,606.14View SEC Filing  
12/9/2014Bruce C CozaddCEOSell5,000$178.79$893,950.00View SEC Filing  
12/9/2014Suzanne Sawochka HooperEVPSell1,852$178.79$331,119.08View SEC Filing  
12/1/2014Patrick G EnrightDirectorSell10,000$172.74$1,727,400.00View SEC Filing  
11/24/2014Jeffrey K TobiasCMOSell4,598$170.12$782,211.76View SEC Filing  
11/7/2014Iain McgillSVPSell7,066$172.03$1,215,563.98View SEC Filing  
10/10/2014Jeffrey K TobiasCMOSell1,000$154.04$154,040.00View SEC Filing  
10/6/2014Patrick G EnrightDirectorSell10,000$160.56$1,605,600.00View SEC Filing  
9/25/2014Seamus MulliganDirectorSell50,000$163.16$8,158,000.00View SEC Filing  
9/24/2014Seamus MulliganDirectorSell35,294$163.70$5,777,627.80View SEC Filing  
9/12/2014Jeffrey K TobiasCMOSell1,000$171.22$171,220.00View SEC Filing  
9/11/2014Karen J WilsonSVPSell3,000$175.00$525,000.00View SEC Filing  
9/11/2014Seamus MulliganDirectorSell50,000$175.00$8,750,000.00View SEC Filing  
9/9/2014Bruce C CozaddCEOSell5,000$170.32$851,600.00View SEC Filing  
9/8/2014Karen J WilsonSVPSell2,500$170.00$425,000.00View SEC Filing  
9/8/2014Suzanne Sawochka HooperEVPSell1,852$168.00$311,136.00View SEC Filing  
8/12/2014Bruce C CozaddCEOSell5,000$133.15$665,750.00View SEC Filing  
8/12/2014Suzanne Sawochka HooperEVPSell1,185$133.15$157,782.75View SEC Filing  
8/11/2014Jeffrey K TobiasCMOSell4,933$135.42$668,026.86View SEC Filing  
7/8/2014Bruce C CozaddCEOSell5,000$155.00$775,000.00View SEC Filing  
7/8/2014Suzanne Sawochka HooperEVPSell1,853$155.00$287,215.00View SEC Filing  
7/7/2014Karen J WilsonSVPSell2,500$165.00$412,500.00View SEC Filing  
6/25/2014Seamus MulliganDirectorSell50,000$149.69$7,484,500.00View SEC Filing  
6/20/2014Russell J CoxCOOSell2,000$155.00$310,000.00View SEC Filing  
6/17/2014Fintan KeeganEVPSell3,750$150.00$562,500.00View SEC Filing  
6/10/2014Bruce C CozaddCEOSell5,000$142.34$711,700.00View SEC Filing  
5/16/2014Jeffrey TobiasCMOSell1,000$128.01$128,010.00View SEC Filing  
5/13/2014Bruce CozaddCEOSell5,000$128.92$644,600.00View SEC Filing  
4/17/2014Rick WinninghamDirectorSell27,500$140.00$3,850,000.00View SEC Filing  
4/14/2014Jeffrey TobiasCMOSell3,000$128.54$385,620.00View SEC Filing  
4/8/2014Bruce CozaddCEOSell5,000$123.18$615,900.00View SEC Filing  
3/10/2014Jeffrey TobiasCMOSell3,000$152.99$458,970.00View SEC Filing  
3/6/2014Fintan KeeganEVPSell4,640$159.90$741,936.00View SEC Filing  
3/4/2014Seamus MulliganDirectorSell550,000$156.25$85,937,500.00View SEC Filing  
3/3/2014Patrick EnrightDirectorSell559,628$152.39$85,281,710.92View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
realistinvestor.com logoDeferred Tax Assets Of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) At $50.006 Millions - RealistInvestor.com (NASDAQ:JAZZ)
www.realistinvestor.com - February 17 at 5:23 PM
sbwire.com logoNarcolepsy Treatment Market Is Expected to Gain Popularity Across the Globe (NASDAQ:JAZZ)
www.sbwire.com - February 16 at 8:05 AM
finance.yahoo.com logoJazz Pharmaceuticals to Report 2016 Fourth Quarter and Full Year Financial Results on February 28, 2017 (NASDAQ:JAZZ)
finance.yahoo.com - February 14 at 7:27 PM
News IconLarge Outflow of Money Witnessed in Jazz Pharmaceuticals plc - Highland Mirror (NASDAQ:JAZZ)
www.highlandmirror.com - February 13 at 11:03 AM
nasdaq.com logoBullish Two Hundred Day Moving Average Cross - JAZZ - Nasdaq - Nasdaq (NASDAQ:JAZZ)
www.nasdaq.com - February 9 at 6:59 PM
prnewswire.com logoJazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 ... - PR Newswire (press release) (NASDAQ:JAZZ)
www.prnewswire.com - February 9 at 6:59 PM
nasdaq.com logoAGTC On Watch, It's Advantage REGN, No Need For FDA Panel Review For Betrixaban (NASDAQ:JAZZ)
www.nasdaq.com - February 9 at 4:53 AM
streetinsider.com logoJazz Pharmaceuticals (JAZZ) Says First Patient Enrolled in Phase 2 Study of JZP-110 for Excessive Sleepiness in Parkinson's Disease (NASDAQ:JAZZ)
www.streetinsider.com - February 8 at 6:49 PM
us.rd.yahoo.com logoJazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Study Evaluating JZP-110 for Excessive Sleepiness in Parkinson's Disease (NASDAQ:JAZZ)
us.rd.yahoo.com - February 8 at 6:49 PM
us.rd.yahoo.com logo4:06 pm Jazz Pharma announces that the first patient has been enrolled in a Phase 2 clinical study evaluating JZP-110 (NASDAQ:JAZZ)
us.rd.yahoo.com - February 8 at 6:49 PM
News IconWhy Jazz Pharmaceuticals PLC's Shareholders Didn't Sleep on This 12% Gain in January - Fox Business (NASDAQ:JAZZ)
www.foxbusiness.com - February 5 at 10:47 PM
News IconWhy Jazz Pharmaceuticals PLC's Shareholders Didn't Sleep on This 12% Gain in January - Madison.com (NASDAQ:JAZZ)
host.madison.com - February 4 at 6:03 PM
sbwire.com logoLymphoblastic Lymphoma Market Global Industry Volume and Region Analysis 2024 (NASDAQ:JAZZ)
www.sbwire.com - February 3 at 6:43 PM
News IconWestfield Capital Management Company LP Trimmed Its Jazz Pharmaceuticals Plc (JAZZ) Position by $17.77 Million (NASDAQ:JAZZ)
randolphguide.com - February 3 at 6:43 PM
fool.com logoWhy Jazz Pharmaceuticals PLC's Shareholders Didn't Sleep on This 12% Gain in January (NASDAQ:JAZZ)
www.fool.com - February 3 at 1:58 PM
bizjournals.com logoResearch Reports Initiation on Biotech Stocks -- Jazz Pharma, Infinity Pharma, Acorda Therapeutics, and Ultragenyx Pharma (NASDAQ:JAZZ)
www.bizjournals.com - January 30 at 10:35 AM
investopedia.com logoJazz Pharma Gets FDA Warning for UK Plant (JAZZ) - Investopedia (NASDAQ:JAZZ)
www.investopedia.com - January 27 at 8:07 PM
investopedia.com logoJazz Pharmaceuticals Manufacturing Plant Gets Warning (NASDAQ:JAZZ)
www.investopedia.com - January 27 at 8:07 PM
4-traders.com logoJazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating Defibrotide for the Potential Prevention of VOD in High... (NASDAQ:JAZZ)
www.4-traders.com - January 26 at 7:45 PM
tmcnet.com logoMacroGenics Announces Appointments to Board of Directors (NASDAQ:JAZZ)
www.tmcnet.com - January 25 at 7:27 PM
News IconSell-side is Weighing in on Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Earnings & Targets - Aiken Advocate (NASDAQ:JAZZ)
aikenadvocate.com - January 24 at 3:02 PM
News IconJazz Pharmaceuticals Plc (JAZZ) Stock Value Declined While Partner Fund Management LP Increased Position (NASDAQ:JAZZ)
randolphguide.com - January 23 at 11:20 PM
4-traders.com logoJAZZ PHARMACEUTICALS PLC : Other Events (form 8-K) (NASDAQ:JAZZ)
www.4-traders.com - January 20 at 12:50 AM
finance.yahoo.com logoCan Jazz Pharmaceuticals Be a Top Choice for Value Investors? (NASDAQ:JAZZ)
finance.yahoo.com - January 19 at 7:48 PM
capitalcube.com logoJazz Pharmaceuticals Plc: Leads amongst peers with strong fundamentals (NASDAQ:JAZZ)
www.capitalcube.com - January 19 at 7:48 PM
investopedia.com logoFDA Approves Generic of Jazz’s Sleep Drug (JAZZ) (NASDAQ:JAZZ)
www.investopedia.com - January 18 at 6:34 PM
kcregister.com logoFDA approve the first generic version of Jazz Pharmaceuticals (NASDAQ:JAZZ)’s Xyrem, to treat patients with narcolepsy (NASDAQ:JAZZ)
www.kcregister.com - January 18 at 6:34 PM
schaeffersresearch.com logoStocks On the Move: Apricus Biosciences Inc, Jazz Pharmaceuticals plc, and Cameco Corp (NASDAQ:JAZZ)
www.schaeffersresearch.com - January 18 at 6:34 PM
smarteranalyst.com logoCantor Cheers As Jazz Pharmaceuticals plc Shares Rise 9% (NASDAQ:JAZZ)
www.smarteranalyst.com - January 18 at 6:34 PM
biz.yahoo.com logoJAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Other Events (NASDAQ:JAZZ)
us.rd.yahoo.com - January 18 at 6:34 PM
us.rd.yahoo.com logoFDA Approves Generic of Jazz Pharma's Sleep Drug (NASDAQ:JAZZ)
us.rd.yahoo.com - January 18 at 6:34 PM
investors.com logoJazz Rebuffs Concerns Of Generic Sleep Drug Amid Patent Litigation (NASDAQ:JAZZ)
www.investors.com - January 18 at 6:34 PM
streetinsider.com logoJazz Pharmaceuticals (JAZZ) Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating Defibrotide for Prevention of VOD (NASDAQ:JAZZ)
www.streetinsider.com - January 17 at 11:27 PM
News IconJazz Pharmaceuticals Announces First Patient Enrolled in Phase 3... (NASDAQ:JAZZ)
www.aboutpharma.com - January 17 at 11:27 PM
smarteranalyst.com logoFirst Patient Enrolled in Jazz Pharmaceuticals plc (JAZZ) Phase 3 Trial of Defibrotide for the Potential Prevention of VOD (NASDAQ:JAZZ)
www.smarteranalyst.com - January 17 at 11:27 PM
4-traders.com logoJazz Pharmaceuticals : FDA approves generic version of Jazz Pharma's sleep disorder drug (NASDAQ:JAZZ)
www.4-traders.com - January 17 at 6:27 PM
finance.yahoo.com logoJazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating Defibrotide for the Potential Prevention of VOD in High Risk Patients (NASDAQ:JAZZ)
finance.yahoo.com - January 17 at 6:26 PM
finance.yahoo.com logo4:05 pm Jazz Pharma announces that the first patient has been enrolled in a Phase 3 clinical trial comparing the efficacy and safety of defibrotide versus best supportive care (:BSC) (NASDAQ:JAZZ)
finance.yahoo.com - January 17 at 6:26 PM
finance.yahoo.com logoFDA approves generic version of Jazz Pharma's sleep disorder drug (NASDAQ:JAZZ)
finance.yahoo.com - January 17 at 6:26 PM
investors.com logoNeurocrine Med Failure, Jazz Pharma Generic Rival OK Sends Both Down (NASDAQ:JAZZ)
www.investors.com - January 17 at 6:26 PM
News IconWill The Needle Move For Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:JAZZ)
wsbeacon.com - January 16 at 6:01 PM
realistinvestor.com logoQuarterly Deferred Tax Assets Of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) At $50.006 Millions - RealistInvestor.com (NASDAQ:JAZZ)
www.realistinvestor.com - January 12 at 6:32 PM
biz.yahoo.com logoJAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and (NASDAQ:JAZZ)
biz.yahoo.com - January 9 at 6:44 PM
realistinvestor.com logoResearch Analysts Set Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Price Target at $176.181 - RealistInvestor.com (NASDAQ:JAZZ)
www.realistinvestor.com - January 9 at 3:51 AM
News IconNo fake sales of Soliris, Alexion says (NASDAQ:JAZZ)
www.providencejournal.com - January 8 at 10:50 PM
News IconTeva Pharmaceutical Industries Limited (NYSE:TEVA) (NASDAQ:JAZZ)
avauncer.com - January 8 at 5:48 PM
News IconTeva Pharmaceutical issues 2017 guidance that is below expectations (NASDAQ:JAZZ)
jagsreport.com - January 8 at 1:01 AM
investornewswire.com logoJazz Pharmaceuticals plc (NASDAQ:JAZZ) Records An Impact Score Of 100 - Investor Newswire (NASDAQ:JAZZ)
www.investornewswire.com - January 5 at 7:22 PM
prnewswire.com logoJazz Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference on January 9 - PR Newswire (press release) (NASDAQ:JAZZ)
www.prnewswire.com - January 5 at 7:22 PM
News IconHere's Why Jazz Pharmaceuticals PLC Fell Out of Tune and Lost 22% in 2016 - Madison.com (NASDAQ:JAZZ)
host.madison.com - January 5 at 7:22 PM


What is Jazz Pharmaceuticals PLC's stock symbol?

Jazz Pharmaceuticals PLC trades on the NASDAQ under the ticker symbol "JAZZ."

Where is Jazz Pharmaceuticals PLC's stock going? Where will Jazz Pharmaceuticals PLC's stock price be in 2017?

16 analysts have issued 1-year target prices for Jazz Pharmaceuticals PLC's shares. Their predictions range from $148.00 to $210.00. On average, they expect Jazz Pharmaceuticals PLC's share price to reach $181.85 in the next twelve months.

When will Jazz Pharmaceuticals PLC announce their earnings?

Jazz Pharmaceuticals PLC is scheduled to release their next quarterly earnings announcement on Tuesday, February, 21st 2017.

What are analysts saying about Jazz Pharmaceuticals PLC stock?

Here are some recent quotes from research analysts about Jazz Pharmaceuticals PLC stock:

  • Mizuho analysts commented, "We remain bullish on the stock in front of a widely anticipated Xyrem settlement and pipeline catalysts in 1H:17. Jazz has also retained M&A capacity while many of its peers remain overlevered. We are modeling 4Q:16 revenue of $399.8M and EPS of $2.73 relative to consensus estimates $398.9M and $2.65 and the implied guidance ranges of $394-$439M and $2.44-$2.84. We note that Jazz pre-announced at a recent investor conference, indicating that it expects to meet 2016 revenue guidance. We reiterate our Buy rating and raise our PT to $152 from $127." (2/21/2017)
  • Cantor Fitzgerald analysts commented, "Xyrem patent litigation court date could be around the corner. A trial is scheduled for May 1 and management believes it is likely that the proceeding will commence on that date. Before then, however, a Markman hearing may be held related to a recent Orange Book-listed patent." (1/12/2017)

  • According to Zacks Investment Research, "Jazz reported better-than-expected earnings in Q3 while revenue fell short of the estimate. Jazz’s sleep disorder drug Xyrem is the only FDA approved product for both cataplexy and EDS. Its lead pipeline candidate, JZP-110, being developed for the treatment of EDS in patients suffering from narcolepsy and OSA, complements its existing sleep disorder portfolio. In October, Jazz commenced a rolling submission for its second pipeline candidate, Vyxeos and plans to finish it in early 2017. We believe Vyxeos has multi-million dollar potential.  However, Xyrem, is facing patent challenges and some of Xyrem’s patents are undergoing inter partes review. Jazz has also been facing challenges in building sufficient inventory levels for Erwinaze due to constrained manufacturing capacity and may experience further supply disruptions in certain markets, including the U.S., from time to time." (11/14/2016)

  • Barclays PLC analysts commented, "We think JAZZ’s 2Q earnings report should be viewed in the context of the future of JAZZ rather than its present form. Xyrem remains JAZZ’s biggest product, while growing nicely as maturing which mgmt implicitly acknowledged by noting a slowing in rates of narcolepsy diagnosis. Xyrem revenues came in at $281M, below our $286M but above consensus at $279. More importantly, the Defitelio US launch posted strong revenues of $9.5M, with global revenues of $33M. The strength of the U.S. launch was a good sign for the product’s potential here, but we think JAZZ deserves credit for the improvement in Europe following sales mgmt changes. EPS of $2.63 came in below our $2.90 and consensus at $2.80, though the shortfall is largely explained by non-GAAP tax changes to reflect recent SEC guidance; JAZZ’s cash taxes are unchanged. The tax change reduced 2Q EPS by $0.19 on an apples-to-apples basis. JAZZ updated EPS guidance to $9.90-$10.30, down from the prior $11.10-$11.50, which reflects the change in tax treatment ($0.55), expenses related to Celator ($0.55) as well as supply constraints for Erwinase and higher R&D expense for JZP-110 ($0.10)." (8/10/2016)

Who owns Jazz Pharmaceuticals PLC stock?

Jazz Pharmaceuticals PLC's stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (12.47%), Renaissance Technologies LLC (2.61%), FIL Ltd (2.04%), Janus Capital Management LLC (1.67%), Tourbillon Capital Partners L.P. (1.38%) and State Street Corp (1.31%). Company insiders that own Jazz Pharmaceuticals PLC stock include Bruce C Cozadd, Heather Ann Mcsharry, Karen J Wilson, Karen L Smith, Kenneth W O'keefe, Michael Patrick Miller, Patrick G Enright, Paul Treacy, Rick E Winningham, Russell J Cox, Seamus Mulligan and Suzanne Sawochka Hooper.

Who sold Jazz Pharmaceuticals PLC stock? Who is selling Jazz Pharmaceuticals PLC stock?

Jazz Pharmaceuticals PLC's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, FIL Ltd, Fiera Capital Corp, Marshall Wace LLP, Asset Management One Co. Ltd., State Street Corp, J. Goldman & Co LP and Brown Capital Management LLC. Company insiders that have sold Jazz Pharmaceuticals PLC stock in the last year include Bruce C Cozadd, Heather Ann Mcsharry, Karen J Wilson, Michael Patrick Miller, Patrick G Enright, Paul Treacy, Rick E Winningham, Russell J Cox and Seamus Mulligan.

Who bought Jazz Pharmaceuticals PLC stock? Who is buying Jazz Pharmaceuticals PLC stock?

Jazz Pharmaceuticals PLC's stock was bought by a variety of institutional investors in the last quarter, including Tourbillon Capital Partners L.P., Renaissance Technologies LLC, Orbimed Advisors LLC, Clough Capital Partners L P, Perceptive Advisors LLC, AQR Capital Management LLC, A.R.T. Advisors LLC and Lumina Fund Management LLC. Company insiders that have bought Jazz Pharmaceuticals PLC stock in the last two years include Karen L Smith and Kenneth W O'keefe.

How do I buy Jazz Pharmaceuticals PLC stock?

Shares of Jazz Pharmaceuticals PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Jazz Pharmaceuticals PLC stock cost?

One share of Jazz Pharmaceuticals PLC stock can currently be purchased for approximately $135.93.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Chart for Tuesday, February, 21, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Earnings History Chart

Earnings by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Dividend History Chart

Dividend Payments by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Last Updated on 2/21/2017 by MarketBeat.com Staff